...
首页> 外文期刊>Journal of Medicinal Chemistry >Design, Synthesis, and Characterization of Globular Orphan Nuclear Receptor Regulator with Biological Activity in Soft Tissue Sarcoma
【24h】

Design, Synthesis, and Characterization of Globular Orphan Nuclear Receptor Regulator with Biological Activity in Soft Tissue Sarcoma

机译:球形孤儿核受体调节剂的设计,合成和表征软组织肉瘤生物活性

获取原文
获取原文并翻译 | 示例
           

摘要

Sarcomas are rare and heterogeneous cancer variants of mesenchymal origin. Their genetic heterogeneity coupled with uncertain histogenesis makes them difficult to treat and results in poor prognosis. In this work, we show that structure-based drug discovery involving computational modeling can be used to identify a new retinoid X receptor (RXR) agonist ligand with a bis(indolyl)methane scaffold. This agent co-self-assembles with an amphiphilic diblock copolymer resulting in nanoparticles (Nano-RXR) with excellent kinetic stability, which were evaluated for efficacy and safety in transformed sarcoma cells, 63-3 Cre and 141-10 Cre of pig origin, and in rodent xenograft models. Responses at gene and protein levels established the treatment approach as a highly effective RXR agonist across cell, rodent, and "Oncopig" models. Interestingly, Nano-RXR was not only able to modulate metabolic and transporter genes related to orphan nuclear receptors but also played a major role in modulating programmed cell death in sarcomas developed in Oncopigs.
机译:肉瘤是罕见的,间充质起源的肿瘤异质性变异。他们加上不确定的组织发生遗传异质性使得它们难以治疗和预后效果差。在这项工作中,我们表明,基于结构的药物发现,涉及的计算模型可以用来确定一个新的视黄醇X受体(RXR)激动剂配有双(吲哚)甲烷支架。这个代理共同自组装,由此导致纳米颗粒具有优良的动力学稳定性的两亲性嵌段共聚物(纳米RXR),将其在转化的肉瘤细胞评价了有效性和安全性,63-3的Cre和猪来源的酶Cre 141-10,在啮齿动物异种移植模型。在基因和蛋白水平响应成立了治疗方法,因为整个细胞,啮齿动物一个非常有效的RXR激动剂和“Oncopig”的车型。有趣的是,纳米RXR不仅能够调节与孤儿核受体的代谢和转运蛋白基因,但在Oncopigs开发肉瘤调节程序性细胞死亡也发挥了重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号